Repurposing chlorpromazine in the treatment of glioblastoma multiforme: analysis of literature and forthcoming steps.
Claudia AbbruzzeseSilvia MatteoniMichele PersicoVeronica VillaniMarco G PaggiPublished in: Journal of experimental & clinical cancer research : CR (2020)
On these bases, and assisted by the information on the well-established chlorpromazine toxicity and dosage in humans, we designed a Phase II clinical trial involving the combination of chlorpromazine with the standard treatment, temozolomide, in the adjuvant phase of the therapeutic protocol. Patients displaying hypo-methylation of the MGMT gene, and thus intrinsically resistant to temozolomide, will be enrolled. The endpoints of this study are the analysis of toxicity and clinical activity, as evaluated in terms of Progression-Free Survival, of the association of chlorpromazine with the first-line treatment for this very serious form of cancer.
Keyphrases
- clinical trial
- phase ii
- newly diagnosed
- free survival
- open label
- end stage renal disease
- oxidative stress
- chronic kidney disease
- systematic review
- genome wide
- ejection fraction
- early stage
- healthcare
- squamous cell carcinoma
- prognostic factors
- dna methylation
- phase iii
- double blind
- health information
- social media
- squamous cell
- childhood cancer